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ATAC = Arimidex, tamoxifen, alone or in combination; CGH = comparative genomic hybridisation; CMF = phosphamide, methotrexate and 5-fluo-
rouracil; DCIS = ductal carcinoma in situ; ER = oestrogen receptor; HER = human endothelial growth factor receptor; MSP = methylation-specific
PCR; VEGF = vascular endothelial growth factor.
Available online http://breast-cancer-research.com/content/6/1/E1
Introduction
The 8th Nottingham International Breast Cancer Confer-
ence was targeted towards scientists and healthcare pro-
fessionals involved in breast cancer treatment and
research. The meeting attracted about 900 delegates
comprising surgeons, oncologists, radiologists, patholo-
gists, scientists, and breast care and research nurses from
both Europe and worldwide. Abstracts of submitted
papers were published in the European Journal of Cancer
[1].
Endocrine – biology and clinical
A comprehensive overview of the functional role of oestro-
gen receptor β (ERβ) in breast cancer was provided by
Professor J-Å Gustavson from Sweden. Since its initial
cloning in 1996, the precise role of ERβ in breast cancer
remains ambiguous. Data were presented to suggest an
anti-proliferative role of ERβ in protecting against abnor-
mal cellular proliferation and cancer development in
several tissue types including breast and prostate. The
use of an ERβ knockout mouse model additionally implies
a functional role of the receptor subtype in the mainte-
nance of tissue integrity. Mice deficient in ERβ protein
display a decreased expression of the basement mem-
brane components collagen and laminin, suggesting an
anti-metastatic role for ERβ. The putative anti-proliferative
function of ERβ was further reiterated by Dr A Shaaban
(University of Liverpool and Clatterbridge Cancer
Research Trust, UK). By using immunohistochemical stain-
ing techniques a progressive loss of ERβ protein was
demonstrated from breast hyperplasia through to ductal
carcinoma in situ (DCIS) and invasive cancer in compari-
son with normal tissue. The potential epigenetic mecha-
nisms accounting for ER loss during breast cancer
progression were discussed in presentations by Dr F
Cooke (Mater Misericordiae Hospital, Dublin, Ireland) and
Dr V Speirs (University of Leeds, UK). The technique of
methylation-specific polymerase chain reaction (MSP) is a
method of reliably identifying ER transcriptional silencing
occurring as a result of promoter hypermethylation. Con-
cordances of 61% and 65% were reported between MSP
profiles and immunohistochemical staining for ERα and
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Abstract
The four-day biennial 8th Nottingham Breast Cancer Conference held at the East Midlands
Conference Centre, University of Nottingham, UK (16–19 September 2003) once again proved to be
a successful event. Recent advances in clinical and scientific research were presented to an
international audience, covering a broad spectrum of breast cancer issues including prediction,
diagnosis and treatment. Delegates were encouraged to participate in workshop sessions, which
allowed the comprehensive discussion of existing and promising future advances in breast cancer
care.
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ERβ, respectively. The data suggest potential applications
of this technique in the prediction of patient response to
adjuvant endocrine therapy and in the identification of
resistant tumours.
Future of endocrine treatment of breast cancer
The future of endocrine treatment for breast cancer is cur-
rently uncertain since the interim analysis of the Arimidex,
tamoxifen, alone or in combination (ATAC) trial [2]. The
third-generation aromatase inhibitors are currently chal-
lenging the supremacy of tamoxifen as the ‘gold standard’
treatment for post-menopausal breast cancer. With a
median follow-up of 47 months, the ATAC trial data con-
tinues to demonstrate superiority for anastrazole in terms
of disease-free survival and the development of contralat-
eral breast cancer [3]. Plans are currently in progress to
produce tissue microarrays from the tumours excised from
patients treated in the ATAC trial. This would subse-
quently permit the evaluation of the various markers asso-
ciated with tumour recurrence and response to the
therapies used within the ATAC trial. To illustrate, human
endothelial growth factor receptor 2 (HER2) and other
cell-surface growth factor receptors are proposed to
cross-talk with the ER via pathways involving mitogen-acti-
vated protein kinase. Evidence exists that tumours overex-
pressing HER2 are resistant to tamoxifen but might be
more sensitive to the inhibitory effects of anastrazole. The
use of an ATAC tissue microarray would allow the investi-
gation of this hypothesis.
Randomised clinical trials have previously shown the pure
anti-oestrogen Faslodex to be as effective as anastrazole
in reducing time to progression in patients with advanced
breast cancer. New data were presented showing equiva-
lent overall survival in patients treated with Faslodex in
comparison with anastrazole. Faslodex therefore repre-
sents a useful additional drug for the treatment of patients
with advanced disease. Questions still remain about the
exact sequencing of treatment in advanced breast cancer.
After relapse while taking tamoxifen, patients can be
treated with either Faslodex or an aromatase inhibitor such
as exemestane. However, Faslodex might offer an addi-
tional therapy after the failure of aromatase inhibitors.
Predicting and targeting in breast cancer
The future of breast cancer prognostication was explored
in a lecture by the Dutch radiation oncologist Dr H
Bartelink. It is currently acknowledged that a proportion of
breast cancer patients receive excessive treatment,
whereas others remain vulnerable to local recurrence or
relapse and might benefit from more intensive therapy. Dr
Bartelink discussed the potential role of DNA microarray
analysis in the prediction of tumour response to radiother-
apy, chemotherapy, endocrine agents and other potential
drugs. Data were presented from an expression array
study of 78 breast tumours, revealing a subset of
70 genes that predict for the onset of distant metastases
within 5 years. These include several genes encoding pro-
teins involved in cell cycle progression, invasion and
angiogenesis. Comparative genomic hybridisation (CGH)
microarray data presented by Dr C Witton (Royal Infirmary
Glasgow, UK, and Vysis Inc, Downers Grove, IL, USA)
similarly characterised several genes putatively involved in
breast cancer development. DNA from 100 breast tumour
specimens was retrospectively analysed to reveal the
amplification of genes involved in cell cycle progression
and survival, including CCND1, AKT1, INSR, AKT2 and
EGFR. This technology might prove clinically useful in the
prediction of disease progression and patient response to
new and existing therapies. The banking of tissue speci-
mens from prospective randomised trials might addition-
ally yield valuable information about the specific genes
associated with response to various treatments.
Tissue retention and patient consent issues
Translational research is essential for both an increased
understanding of the mechanisms of breast carcinogen-
esis and the development of new therapeutic strategies.
After the Alder Hay debacle in 2000, the issue of tissue
retention and banking has remained in the spotlight,
potentially threatening translational research. These con-
cerns were addressed in a workshop entitled ‘EUROPA
DONNA – issues surrounding the retention of tissues for
breast cancer research’. EUROPA DONNA (http://www.
cancerworld.org/progetti/cancerworld/europadonna/pagine/
home/homeframeeudonna.html) is a women’s breast
cancer advocacy organisation representing the views of
women from 27 European member states, drawing atten-
tion to the need for improved breast cancer services and
research.
In the UK since Alder Hay, most concerns about tissue
retention have originated from the government and profes-
sional medical organisations; little regard has been given
to the opinions of the breast cancer patient. This has been
addressed by four independent groups within the UK: first,
a consortium representing Addenbrooke’s Hospital, Cam-
bridge, and the Universities of Leicester and Nottingham;
second, the Institute of Cancer Research and Royal
Marsden Hospital, Sutton, for the Trial Management
Groups and Trial Steering Committees for START (Stan-
dardisation of Radiotherapy) and TACT (Taxotere as Adju-
vant Chemotherapy); third, Nottingham City Hospital; and
fourth, the Leeds Teaching Hospitals NHS Trust. The first
three groups used questionnaires to solicit the views of
breast cancer patients undergoing treatment on the issue
of tissue retention, whereas the last used a focus group
consisting of breast cancer patients and ‘non-threatening’
female medical staff. Dr K Burnet (Addenbrooke’s Hospi-
tal, University of Leicester, and University of Nottingham,
UK) reported the outcome of a survey of 96 breast cancer
patients questioned about their views on entry into clinical3
studies. Provided that the studies were fully explained in
lay terms, about three-quarters of patients were willing to
participate in multiple studies. Data presented by Dr L
Johnson (Institute for Cancer Research and Royal
Marsden Hospital, Sutton, for the Trial Management
Groups and Trial Steering Committees for START and
TACT, UK) similarly reported a respective 81.1% and
98.4% of breast cancer patients to be willing to donate
blood and paraffin-embedded tumour samples for use in
medical research. The four studies therefore concluded
that the vast majority of patients have no objection to the
use of their reserve tissue for research purposes. It is
evident from these studies that decisions on tissue reten-
tion should be made through consultation with the
patients involved.
Bone health in breast cancer
The use of bisphosphonates in breast cancer was
reviewed in a presentation by Dr R Leonard. It was con-
cluded that bisphosphonates do have a defined role in the
treatment of both hypercalcaemia of malignancy and bone
metastasis, acting to prevent pain and reduce the risk of
fracture. Still to be established is the adjuvant role of bis-
phosphonates in the prevention of bone metastases and
osteoporosis in breast cancer patients treated with aro-
matase inhibitors. This should be given precedence in
view of the preliminary ATAC results. The AZURE (does
adjuvant zoledronic acid reduce recurrence in patients
with high risk localised breast cancer) and ZFAST
(Zometa-Femara Adjuvant Synergy Trial) trials investigat-
ing the adjuvant use of zoledronic acid seek to provide
answers to these questions, and the results will be of
potential clinical importance.
Goserelin in the adjuvant treatment of breast
cancer
An update of the Zoladex Early Breast Cancer Research
Association (ZEBRA) trial was presented by Professor R
Blamey (Nottingham City Hospital, UK). The trial has
demonstrated equivalent disease-free and overall survival
periods with the anti-androgen goserelin (Zoladex) to
those achieved with standard cyclophospamide,
methotrexate and 5-fluorouracil (CMF) therapy. Goserelin
was found to be better tolerated than CMF by most
patients, suggesting goserelin as an effective alternative to
adjuvant CMF chemotherapy in premenopausal and peri-
menopausal patients with ER-positive and node-positive
early stage breast cancers.
Results were presented by the Austrian Breast and Colo-
rectal Cancer Study Group comparing the combined use
of goserelin and tamoxifen as an alternative to standard
CMF chemotherapy. A statistically significant improvement
in disease-free and recurrence-free survival was observed
in premenopausal patients with hormone-sensitive
stage I/II tumours after the use of goserelin and tamoxifen
as adjuvant therapy. These results were concurrent with
the findings of the Italian Breast Cancer Study Group
(National Cancer Research Institute, Genoa, Italy). Despite
the encouraging evidence from randomised controlled
trials, goserelin is rarely offered as an adjuvant treatment
to eligible premenopausal breast cancer patients. This
issue should be addressed.
Breast cancer risk
Dr G Evans (St Mary’s Hospital and Withington Hospital,
Manchester, UK) presented an evaluation of the various
risk assessment models currently used in the clinic. Three
models in common use historically (Gail, Claus and Ford)
were compared with a more recent model developed by
Tyrer and Cuzick. A failure of the older models is the
underestimation of actual risk for women with a family
history of breast cancer, suggesting that the Tyrer–Cuzick
model is more accurate in this group of patients. On
behalf of the Irish Breast Screening Programme, Dr S
Boran (Mater Misericordiae Hospital, Dublin, Ireland) pre-
sented encouraging evidence from the newly established
programme for users of hormone replacement therapy.
Although such users are more likely to be recalled for extra
mammography views or biopsy, the actual rates of breast
cancer detection are not increased and those tumours
detected are generally low grade and node negative.
Diagnosis and prognosis
A series of presentations addressing the diagnosis of
breast disease was attended by approximately 150 dele-
gates. Dr K Buhagiar (Western General Hospital, Edin-
burgh, UK) outlined proposals of an electronic proforma
referral letter from general practitioner to specialist, with
the aim of decreasing unnecessary delays in diagnosis.
However, a study investigating the causes of a delay in
breast cancer diagnosis of greater than 2 months identified
several responsible factors such as inadequate imaging,
lack of continuity of care and misinterpretation of results, as
opposed to delays from primary care. Errors in the interpre-
tation of screening mammograms can be avoided by the
arbitration of disparate double readings of the films.
Both fine needle aspiration cytology and core biopsy are
useful tools in the investigation of breast lesions. It was
reported by Dr A Jah (Luton and Dunstable Hospital, UK)
that the combined use of these two tests resulted in
increases in sensitivities for screen-detected and sympto-
matic patients to 80.9% and 89.1%, respectively. It was
therefore recommended that patients should undergo
both investigations during diagnosis, although this will
undoubtedly incur additional expenditure. Core biopsy
results cannot be processed in sufficient time to provide
diagnosis at one-stop breast clinics. As presented by Dr
M Klevesath (West Suffolk Hospital, Bury St Edmonds,
UK) the use of touch imprint cytology of core biopsy spec-
imens before formalin fixation is an accurate method of
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providing immediate results, with a sensitivity of 97% for
predicting malignancy.
Dr G Wishart (Addenbrooke’s Hospital, Cambridge, UK)
compared the established Nottingham Prognostic Indica-
tor score with the computer program ‘Adjuvant!’ [4], which
is designed to assist in decision making about the use of
adjuvant therapy. The use of this program gave an
improved prognosis in 102 of 104 patients discussed at a
‘mock’ multidisciplinary meeting. The clinical implication
for this is that 10 extra patients would not have been
offered chemotherapy, and a further 14 patients predicted
to have marginal benefits would have been given the
option to decide treatment for themselves. As many as
24 patients could potentially have been spared
chemotherapy. Although it was argued that Adjuvant! pro-
vides a more individual prognostic assessment, this
scoring system does not take into account the method of
detection and the fact that screen-detected tumours gen-
erally have a more favourable prognosis.
Biology – growth factors
The HER family (HER1–4) are transmembrane receptor
tyrosine kinases that initiate epidermal growth factor
(EGF) signalling pathways after ligand binding. The HER
proteins are often aberrantly expressed in breast tumours.
A presentation by Dr C Wong (Royal South Hants Hospi-
tal, Southampton, UK) compared the expression of HER2
in younger (19–35 years) and older (55–65 years) breast
cancer patient groups. The expression of HER2 was found
to be more prevalent in the younger patient cohort,
inversely correlating with ER status. It was proposed that
younger patients should be routinely tested for HER2
expression, to permit the modification of treatment regi-
mens and the early use of Herceptin where appropriate.
Serum and tissue concentrations of HER2 were com-
pared in a study presented by Dr C Shaw (Mater Miseri-
cordiae Hospital, Dublin, Ireland). The analysis of samples
from 151 breast cancer patients revealed no correlation
between the HER2 concentration in serum and that in
tissue. However, high concentrations of serum HER2 at
the time of diagnosis were associated with high-grade
disease, suggesting serum HER2 as a potential prognos-
tic indicator. The potential mechanisms of growth inhibi-
tion by Herceptin were investigated by Dr C McMonagle
(University College Hospital, Galway, Ireland). Cell cycle
arrest of HER2-positive breast cancer cells in response to
Herceptin was correlated with the downregulation of 59%
of the cell cycle genes involved in proliferation, as deter-
mined by complementary DNA microarray analysis.
Presentations by Dr S Tovey (Royal Infirmary, Glasgow,
UK) and Dr G Boland (University Hospital of South Man-
chester, UK) discussed the putative role of HER1–4 in
breast cancer. The expression of HER1–4 proteins in
55 primary breast tumours was compared with the prolif-
eration rate, as determined by the incorporation of bro-
modeoxyuridine. A direct association was observed
between HER1–3 positivity and a high rate of cellular pro-
liferation, while HER4 expression was correlated with a
low proliferation rate. In DCIS tumour specimens the
expression of HER4 was associated with positive ER
status and a low proliferation rate, suggesting HER4 as a
favourable prognostic marker.
Scientific interest in angiogenic markers remains high, and
circulating vascular endothelial growth factor (VEGF) con-
centrations are generally elevated in breast cancer
patients. The angiogenic activity of VEGF is negatively
regulated by the soluble receptor, termed sFlt-1. Concen-
trations of circulating VEGF and sFlt-1 were quantified in
the serum of 51 patients with primary invasive breast
cancer, as reported by Dr F Hoar (City Hospital, Birming-
ham, UK). The concentrations of VEGF were higher in the
patient group than in healthy controls, while sFlt-1 concen-
trations remained similar in both groups, reinforcing the
suggestion that the balance of pro-angiogenic and anti-
angiogenic factors is altered during malignant progres-
sion. Data presented by Dr D Morgan (Nottingham City
Hospital, UK) similarly revealed a direct correlation
between the high expression of VEGF-D in the primary
tumour and an increased risk of local recurrence in young
patients with breast cancer (below the age of 40 years).
The potential clinical applications of a novel inhibitor of
VEGF activity, termed ZD6474, were discussed by Dr S
Wedge (AstraZeneca, Macclesfield, UK). Also inhibiting
EGF signalling pathways, ZD6474 has been found to
decrease blood vessel formation and tumour size in
several human xenograft models including breast cancer.
The compound is currently undergoing clinical evaluation
in Phase II trials.
Conclusion
The meeting was conducted in an informal atmosphere,
allowing lively discussion of the issues raised. Recent clin-
ical and scientific advancements were highlighted, with
particular relevance to diagnosis, prognostic indicators
and novel therapeutic strategies. Data were presented
from continuing clinical trials aimed at improving treatment
and offering alternative therapies for premenopausal and
postmenopausal patients with advanced and metastatic
disease, including those who experience tumour recur-
rence while receiving ‘gold standard’ tamoxifen treatment.
Promising advances in novel techniques such as tissue
microarrays and CGH are set to revolutionise breast
cancer diagnosis and prediction. These procedures will
permit the more effective characterisation of tumour pro-
files before treatment, allowing the identification of drug-
resistant patients. Patient consent to the use of tumour
samples for translational research is imperative for the
successful improvement of breast cancer management
and patient care in forthcoming years.
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